Literature DB >> 22579083

Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure.

Michael Egstrup1, Morten Schou, Christian D Tuxen, Caroline N Kistorp, Per R Hildebrandt, Finn Gustafsson, Jens Faber, Jens-Peter Goetze, Ida Gustafsson.   

Abstract

Our aim was to assess the prognostic impact of a high-sensitivity cardiac troponin T (hs-cTnT) assay in an outpatient population with chronic systolic left ventricular heart failure (HF). Four hundred sixteen patients with chronic HF and left ventricular ejection fraction ≤ 45% were enrolled in a prospective cohort study. In addition to hs-cTnT, plasma amino-terminal pro-B-type natriuretic peptide was measured at baseline. Mean age was 71 years, 29% were women, 62% had coronary artery disease (CAD), mean left ventricular ejection fraction was 31%, and 57% had abnormal level of hs-cTnT. During 4.4 years of follow-up, 211 (51%) patients died. In multivariate Cox regression models, hs-cTnT was categorized as quartiles or dichotomized by the 99th percentile of a healthy population. Adjusted hazard ratios for all-cause mortality for quartiles 2 to 4, with quartile 1 as reference, were 1.4 (95% confidence interval 0.9 to 2.4, p = 0.16) for quartile 2, 1.7 (0.9 to 2.5, p = 0.12) for quartile 3, and 2.6 (1.6 to 4.4, p <0.001) for quartile 4 and 1.7 (1.2 to 2.5, p = 0.003) for abnormal versus normal level of hs-cTnT. In patients without CAD, quartile 4 of hs-cTnT was associated with an adjusted hazard ratio of 6.8. In conclusion, hs-cTnT is increased in most outpatients with chronic systolic HF and carries prognostic information beyond clinical parameters and amino-terminal pro-B-type natriuretic peptide. Increased hs-cTnT indicated a particularly deleterious prognosis in patients without CAD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579083     DOI: 10.1016/j.amjcard.2012.04.033

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure.

Authors:  Justin L Grodin; Sarah Neale; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Am J Med       Date:  2014-10-15       Impact factor: 4.965

2.  Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin; Parul U Gandhi; Arianna Belcher; Rory B Weiner; Aaron L Baggish; Jackie Szymonifka; James L Januzzi
Journal:  J Cardiovasc Transl Res       Date:  2015-03-17       Impact factor: 4.132

Review 3.  Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment.

Authors:  Gina Mentzer; Eileen M Hsich
Journal:  Heart Fail Clin       Date:  2018-10-24       Impact factor: 3.179

Review 4.  Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.

Authors:  Alberto Palazzuoli; Serge Masson; Claudio Ronco; Alan Maisel
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

5.  Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial.

Authors:  Milton Packer; James L Januzzi; Joao Pedro Ferreira; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Martina Brueckmann; Waheed Jamal; Daniel Cotton; Tomoko Iwata; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2021-06-21       Impact factor: 17.349

6.  ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.

Authors:  Nadia Aspromonte; Michele Massimo Gulizia; Aldo Clerico; Giuseppe Di Tano; Michele Emdin; Mauro Feola; Massimo Iacoviello; Roberto Latini; Andrea Mortara; Roberto Valle; Gianfranco Misuraca; Claudio Passino; Serge Masson; Alberto Aimo; Marcello Ciaccio; Marco Migliardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

7.  True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study.

Authors:  Mark Mariathas; Rick Allan; Sanjay Ramamoorthy; Bartosz Olechowski; Jonathan Hinton; Martin Azor; Zoe Nicholas; Alison Calver; Simon Corbett; Michael Mahmoudi; John Rawlins; Iain Simpson; James Wilkinson; Chun Shing Kwok; Paul Cook; Mamas A Mamas; Nick Curzen
Journal:  BMJ       Date:  2019-03-13

8.  Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.

Authors:  Taro Narumi; Tetsuro Shishido; Nobuyuki Kiribayashi; Shinpei Kadowaki; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Takehiko Miyashita; Takuya Miyamoto; Tetsu Watanabe; Yoko Shibata; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Exp Diabetes Res       Date:  2012-10-10

9.  Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).

Authors:  Ruth F Dubin; Yongmei Li; Jiang He; Bernard G Jaar; Radhakrishna Kallem; James P Lash; Gail Makos; Sylvia E Rosas; Elsayed Z Soliman; Ray R Townsend; Wei Yang; Alan S Go; Martin Keane; Christopher Defilippi; Rakesh Mishra; Myles Wolf; Michael G Shlipak
Journal:  BMC Nephrol       Date:  2013-10-22       Impact factor: 2.388

10.  Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.

Authors:  Faiez Zannad; Barry Greenberg; John G F Cleland; Mihai Gheorghiade; Dirk J van Veldhuisen; Mandeep R Mehra; Stefan D Anker; William M Byra; Min Fu; Roger M Mills
Journal:  Eur J Heart Fail       Date:  2015-04-27       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.